首页> 外文期刊>Tumour biology : >Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma
【24h】

Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma

机译:B7-H1和B7-H4表达水平作为肾细胞癌独立预测指标的预后研究

获取原文
获取原文并翻译 | 示例
           

摘要

In order to evaluate the correlation of B7-H4 and B7-H1 with renal cell carcinoma (RCC), we analyzed B7-H1 and B7-H4 expressions and their clinical significance by immunohistochemical method. Our result indicated that B7-H4-positive staining was detected in 58.13 % of RCC tissues (25 tissues tumors), and there were 18 tissues of patients without detectable B7-H4. Furthermore, 21 cases (48.83 %) were B7-H1-positive. Positive tumor expressions of B7-H4 and B7-H1 were markedly related to advanced TNM stage (P = 0.001; P = 0.014), high grade (P = 0.001; P = 002), and larger tumor size (P = 0.002; P = 024) in RCC tissues than patients with B7-H4-negative and B7-H1-negative in RCC tissues. The patients with B7-H1 and B7-H4-positive expressions were found to be markedly correlated with the overall survival of the patients (P < 0.05) and tended to have an increased risk of death when compared with negative expression groups. Univariate analysis showed that B7-H4 and B7-H1 expressions, TNM stage, high grade, and tumor size were significantly related to the prognosis of RCC. Furthermore, multivariate analysis showed that B7-H4 and B7-H1 expressions decreased overall survival. The adjusted HR for B7-H1 was 2.83 (95 % CI 1.210-2.971; P = 0.031) and also was 2.918 (95 % CI 1.243-3.102; P = 0.006) for B7-H4 that showed these markers were independent prognostic factors in RCC patients. The expressions of B7-H1 and B7-H4 in RCC patients indicate that these markers may be as a predictor of tumor development and death risk. Further investigations can be helpful to confirm B7-H1 and B7-H4 roles as an independent predictor of clinical RCC outcome.
机译:为了评估B7-H4和B7-H1与肾细胞癌(RCC)的相关性,我们通过免疫组织化学方法分析了B7-H1和B7-H4的表达及其临床意义。我们的结果表明,在58.13%的RCC组织(25个组织肿瘤)中检测到B7-H4阳性染色,并且有18个患者组织未检测到B7-H4。此外,有21例(48.83%)是B7-H1阳性。 B7-H4和B7-H1的阳性肿瘤表达与晚期TNM分期(P = 0.001; P = 0.014),高级别(P = 0.001; P = 002)和较大的肿瘤大小(P = 0.002; P = 024),而RCC组织中B7-H4阴性和B7-H1阴性的患者。发现具有B7-H1和B7-H4阳性表达的患者与患者的总体生存率显着相关(P <0.05),并且与阴性表达组相比,死亡风险更高。单因素分析显示,B7-H4和B7-H1的表达,TNM分期,高级别和肿瘤大小与RCC的预后密切相关。此外,多变量分析表明B7-H4和B7-H1表达降低了总生存率。 B7-H1的校正后HR为2.83(95%CI 1.210-2.971; P = 0.031),B7-H4的校正后HR为2.918(95%CI 1.243-3.102; P = 0.006),表明这些标志物是独立的预后因素RCC患者。 RCC患者中B7-H1和B7-H4的表达表明这些标志物可作为肿瘤发展和死亡风险的预测指标。进一步的研究可能有助于确认B7-H1和B7-H4作为临床RCC结局的独立预测因子的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号